Oramed Pharma screens first patients under its Phase 3 oral insulin trial

 

• Oramed Pharmaceuticals (NASDAQ:ORMP) starts Phase 3 trial of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes.
• The first patients were screened at U.S. sites in Oramed's ORA-D-013-1 trial, one of two Phase 3 trials. The trials will recruit a total of 1,125 patients who have inadequate glycemic control over a period of 6 to 12 months and the  efficacy data will become available after all patients have completed the first 6-month treatment period.
• "ORMD-0801 is the first oral insulin capsule to achieve the requisite efficacy and safety data enabling us to run the world's first FDA Phase 3 oral insulin trial. Oramed is proud to lead the field in reaching this very significant diabetes treatment milestone," says CEO Nadav Kidron.
• https://seekingalpha.com/news/3639073-oramed-pharma-screens-first-patients-under-phase-3-oral-insulin-trial-sharesplus-8